Clinical Trial Update: Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of HS022 and Trastuzumab® in Combination With Vinorelbine Bitartrate Injection in the Treatment of HER2-positive Breast Cancer [Phase 3]

View source ↗

Summary

Phase III trial comparing HS022 to trastuzumab in combination with vinorelbine for HER2-positive breast cancer completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HS022
• Trastuzumab (trastuzumab)
• Vinorelbine Bitartrate Injection (vinorelbine)

Snippet

Sponsor: Zhejiang Hisun Pharmaceutical Co. Ltd. | Conditions: HER2-positive Breast Cancer | Phase 3 | Status: COMPLETED